Vesta Real Estate's 15min chart shows RSI Oversold and Bullish Marubozu pattern.
PorAinvest
martes, 2 de septiembre de 2025, 10:02 am ET1 min de lectura
ONC--
The growth was largely attributed to the sales of self-developed products, Brukinsa (zanubrutinib capsules) and Tislelizumab (antibody), as well as products licensed from Amgen. Zanubrutinib, in particular, performed exceptionally well, securing the top position in both the U.S. and global BTK inhibitor markets. Global sales of zanubrutinib reached 12.527 billion yuan in the first half of 2025, with a year-on-year increase of 56.2%. In the U.S. market, sales amounted to 8.958 billion yuan, growing 51.7% year-on-year [1].
The strong performance of BeiGene's stock comes amidst broader market conditions. According to Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels, and a bullish Marubozu candle was observed at 09:00 on February 2, 2025. These indicators suggest that the stock price has declined rapidly and fallen below its fundamental support level, leading to a potential continuation of bullish momentum [2].
References:
[1] https://news.futunn.com/post/61555960/us-stock-market-update-beigene-oncus-surges-over-9-with
[2] https://vesta-real-estate.com/15-minute-chart
VTMX--
Based on the 15-minute chart provided by Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels. Furthermore, the stock has exhibited a bullish Marubozu candle at 09:00 on February 2, 2025. This indicates that the stock price has declined rapidly and fallen below its fundamental support level. Consequently, buyers have taken control of the market, and a continuation of bullish momentum is likely.
On Tuesday, BeiGene (ONC.US) surged over 9%, closing at $334.20. According to Zhitong Finance, the stock's performance was driven by robust financial results in the first half of 2025. BeiGene reported total revenue of 17.518 billion yuan, a 46.03% year-on-year increase, with product revenue reaching 17.36 billion yuan, up 45.8%. The company also recorded a net profit of 450 million yuan, marking its first profit since the beginning of the year [1].The growth was largely attributed to the sales of self-developed products, Brukinsa (zanubrutinib capsules) and Tislelizumab (antibody), as well as products licensed from Amgen. Zanubrutinib, in particular, performed exceptionally well, securing the top position in both the U.S. and global BTK inhibitor markets. Global sales of zanubrutinib reached 12.527 billion yuan in the first half of 2025, with a year-on-year increase of 56.2%. In the U.S. market, sales amounted to 8.958 billion yuan, growing 51.7% year-on-year [1].
The strong performance of BeiGene's stock comes amidst broader market conditions. According to Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels, and a bullish Marubozu candle was observed at 09:00 on February 2, 2025. These indicators suggest that the stock price has declined rapidly and fallen below its fundamental support level, leading to a potential continuation of bullish momentum [2].
References:
[1] https://news.futunn.com/post/61555960/us-stock-market-update-beigene-oncus-surges-over-9-with
[2] https://vesta-real-estate.com/15-minute-chart
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios